Previous 10 | Next 10 |
BOSTON and LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, today...
Centessa Pharmaceuticals (CNTA +10.5%) shares are on the rise after director Francesco De Rubertis purchased 34,326 company shares, worth ~$440K. The shares were purchased at $12.82 in a transaction dated Dec. 02, 2021. Form 4 A look at Centessa's ownership structure: De Rubertis, who is a 10...
Centessa Pharmaceuticals (CNTA +1.6%) Director De Rubertis Francesco who is a 10% owner of the company purchased 97,151 shares at $11.62 - $12.62 worth ~$1.2M on Nov.30. Also, Director Medicxi Ventures Management (Jersey) with 10% ownership acquired 97,151 shares at $11.62 - $12.62. Quic...
Centessa Pharmaceuticals (CNTA +6.1%) Director, Rubertis Francesco De buys 68,523 shares worth $800K. The price ranges from $11.33 - $11.70. Currently, the stock trades at Form 4 The stock has market cap of ~$1B and has dropped about 42% since inception. For further details see: ...
Centessa Pharmaceuticals (NASDAQ:CNTA) sank more than 13% to a record low Monday as the stock’s IPO lockup-period expiration approaches and a one-day rally last Friday ran out of gas. CNTA ended Monday trading at $11.62, down 13.1% on the session and 41.9% from the $20 a share that the...
Centessa Pharmaceuticals (NASDAQ:CNTA): Q3 GAAP EPS of -$0.45. Cash and cash equivalents of $578.8M Press Release For further details see: Centessa Pharmaceuticals reports Q3 results
~ Announced positive topline data from proof-of-concept study of SerpinPC in severe hemophilia A and B subjects not on prophylaxis, demonstrating 88% reduction in median Annualized Bleeding Rate (“ABR”) for all bleeds and 94% reduction in median ABR for spontaneous joint ble...
BOSTON and LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA) today announced that Saurabh Saha, MD, PhD, Chief Executive Officer, will present at the following investor conferences: Event : Jefferies London Healthcare C...
Shares of Centessa Pharmaceuticals (CNTA -15.8%) are down sharply this morning after early data from a phase 1 trial of a candidate for Alpha-1 Antitrypsin Deficiency ("AATD") showed one of three participants experienced a delayed, reversible increase in levels of the liver enzymes ALT and AS...
Gainers: ABVC BioPharma (NASDAQ:ABVC) +250%, ANI Pharmaceuticals (NASDAQ:ANIP) +51%, Artelo Biosciences (NASDAQ:ARTL) +37%, Nutriband (NTRBW) +34%, Regencell Bioscience (NASDAQ:RGC) +15%. Losers: Centessa Pharmaceuticals (NASDAQ:CNTA) -19%, Mi...
News, Short Squeeze, Breakout and More Instantly...
Centessa Pharmaceuticals plc Company Name:
CNTA Stock Symbol:
NASDAQ Market:
Centessa Pharmaceuticals plc Website:
2024-06-21 11:15:04 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for CNTA on June 21, 2024 09:17AM ET. The previous analyst recommendation was Equal-Weight. CNTA was trading at $9.28 at issue of the analyst recommendation. The overall analyst consensus : ...
BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Fi...
Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 interim analysis planned in 2024 Orexin Agonist Program: Cleared IND and initiated Phase 1 first-in-human clinical trial of ORX750, a highly potent and sel...